March 7th 2023
Daniel H. Ahn, DO, discusses the evolution of first-line treatments in advanced hepatocellular carcinoma.
March 6th 2023
Daniel H. Ahn, DO, discusses the importance of drug toxicity when selecting between first-line immune checkpoint inhibitor–based regimens in hepatocellular carcinoma.
October 8th 2021
Daniel H. Ahn, DO, discusses the increased understanding of cholangiocarcinoma.
June 22nd 2021
Daniel H. Ahn, DO, shares how to navigate among the therapeutic options available for patients with advanced, unresectable hepatocellular carcinoma.
June 21st 2021
Daniel H. Ahn, DO, discusses considerations for treatment with atezolizumab and bevacizumab in patients with hepatocellular carcinoma.
June 17th 2021
Daniel H. Ahn, DO, discusses the utility of atezolizumab in combination with bevacizumab in hepatocellular carcinoma.
January 21st 2021
Daniel H. Ahn, DO, discusses the growing role of circulating tumor DNA in colorectal cancer.
November 10th 2020
Daniel H. Ahn, DO, discusses the role of checkpoint inhibitor therapy in patients with microsatellite instability–high colorectal cancer who harbor an NTRK fusion.
October 30th 2020
Daniel H. Ahn, DO, discusses the identification of NTRK alterations in colorectal cancer.
October 27th 2020
Daniel H. Ahn, DO, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high metastatic colorectal cancer.
October 23rd 2020
Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.
July 24th 2020
Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses current limitations of targeted therapy in the colorectal cancer.
July 23rd 2020
Daniel H. Ahn, DO, discusses updated findings from the phase 3 KEYNOTE-177 trial in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer.
July 17th 2020
Daniel H. Ahn, DO, discusses advancing actionable alterations in colorectal cancer.
July 13th 2020
Daniel H. Ahn, DO, discusses left- versus right-sided tumors in colorectal cancer.
August 15th 2018
Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses biomarker-driven strategies in gastric and gastroesophageal junction (GEJ) cancers.
May 24th 2018
Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses targeted therapies in gastric/esophageal cancers.
May 11th 2018
Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses the role of immunotherapy in treating patients with gastric/gastroesophageal cancers.
March 13th 2017
Daniel H. Ahn, DO, internist, Mayo Clinic, discusses advances in neoadjuvant therapies for patients with gastric cancer during the 2017 OncLive State of the Science Summit on Gastrointestinal Malignancies.
February 28th 2017
Daniel H. Ahn, DO, internist, Mayo Clinic, discusses the identification of novel biomarkers in gastric cancer during the 2017 State of the Science Summit on Gastrointestinal Malignancies.